1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Real-time Estimate Cboe BZX  -  09:40 2022-08-15 am EDT
41.83 USD   +0.87%
09:39aNovavax Seeks Emergency Use Authorization From FDA for COVID-19 Vaccine as Booster for Adults
MT
08:19aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:11aNovavax seeks U.S. authorization for COVID vaccine booster
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax expects COVID vaccine targeting Omicron in fourth quarter

07/01/2022 | 02:32pm EDT

July 1 (Reuters) - Novavax Inc said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates development of shots to protect against the BA.4 and BA.5 subvariants.

The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.

Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.

The company's vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)


© Reuters 2022
All news about NOVAVAX, INC.
09:39aNovavax Seeks Emergency Use Authorization From FDA for COVID-19 Vaccine as Booster for ..
MT
08:19aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:11aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:01aNovavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax..
PR
07:47aNovavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine..
AQ
08/12Novavax COVID-19 Vaccine Receives Approval in South Korea for Use in Adolescents
MT
08/12Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescent..
PR
08/12Novavax Vaccine Approved for Adolescents in South Korea
DJ
08/11Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
PR
08/10Novavax Gets Thai Regulator's Emergency Use Authorization for COVID-19 Vaccine for Ages..
MT
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 2 379 M - -
Net income 2022 319 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 10,5x
Yield 2022 -
Capitalization 3 244 M 3 244 M -
EV / Sales 2022 0,31x
EV / Sales 2023 -0,04x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 41,47 $
Average target price 125,83 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-71.01%3 244
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068